Press release - 18/03/2022 Less fossil oil in CO2-reducing plastics The "carbonauten minus CO2 factory 1" will start production of 4,000 t of CO2-reducing plastic granules annually at favorable prices in summer 2022.https://www.biooekonomie-bw.de/en/articles/pm/weniger-erdoel-co2-senkenden-kunststoffen
Press release - 18/03/2022 Lung Tissue from the Lab Laboratory studies of lung tissue usually require the removal of large amounts of human or animal tissue. Now scientists from the University of Freiburg’s Faculty of Medicine have succeeded in collaboration with American researchers in generating tiny quantities of lung tissue, so-called organoids, from just a few body cells in the lab.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lung-tissue-lab
Event - 14/12/2022 - 15/12/2022 Meet & Match Cell and Gene Therapy Online, Meet & Match https://www.bio-pro.de/en/events/meet-match-cell-and-gene-therapy
Event - 19/05/2022 Lunch & Learn Market Access and Opportunities for Medtech Companies in the United Kingdom and Germany Online, Information event https://www.bio-pro.de/en/events/lunch-learn-market-access-and-opportunities-medtech-companies-united-kingdom-and-germany
Lentil cultivation and cleaning on the farm - EIP-AGRI Rhizo-Linse project - 16/03/2022 Lentils return to the Heckengäu region Lentils are among the oldest crop plants in Central European agriculture and were once a popular food in ancient Egypt, Persia and Mesopotamia. The legume was widespread in Germany until the mid-20th century, but has since disappeared completely from farmers’ fields. Over the past decade, lentils have reappeared as a crop grown locally and are cultivated in harmony with nature.https://www.biooekonomie-bw.de/en/articles/news/lentils-return-heckengaeu-region
SolidCAR-T project - 15/03/2022 Modular ‘mini-factories’ for decentralised production of CAR T cells Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.https://www.gesundheitsindustrie-bw.de/en/article/news/modular-mini-factories-decentralised-production-car-t-cells
Press release - 14/03/2022 Do gut bacteria influence treatment success of CAR-T cell therapies? Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
Press release - 10/03/2022 Innovation Day Upper Rhine provides cross-border knowledge transfer Inspiration, innovation, networking are the name of the game on April 12, 2022, when the trinational event “Innovation Day Upper Rhine” (IDUR) takes place at the Palais Universitaire on the University of Strasbourg campus. Twelve universities in the Upper Rhine region, including the University of Freiburg and 100 partner companies of the EU funded project “Knowledge Transfer Upper Rhine” (KTUR), invite to a day of exchange and meeting.https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovation-day-upper-rhine-provides-cross-border-knowledge-transfer
Alternative foodstuff ? - 09/03/2022 Hemp: regional superfood and valuable source of protein If there were a competition for the ‘crop of the future’, hemp would certainly be at the top. But not because of the intoxicating effect of some hemp varieties. Cannabis has the potential to help supply protein in the quantities required by a growing world population – in a sustainable way. The TASTINO project brings together researchers from academia and industry to work on ways to make the regional superfood available as a vegan alternative.https://www.biooekonomie-bw.de/en/articles/news/hemp-regional-superfood-and-valuable-source-protein
Press release - 03/03/2022 Identifying Alzheimer's risks – as early as 17 years before diagnosis In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?https://www.gesundheitsindustrie-bw.de/en/article/press-release/identifying-alzheimers-risks-early-17-years-diagnosis
Elastin as artificial muscle material - 02/03/2022 Artificial muscle from proteins for diverse future applications As far as diversity and complexity are concerned, proteins are nature's smallest marvels. Biotechnologists have already used natural proteins as a basis for the development, bespoke design and production of artificial systems. This is what the livMatS cluster of excellence at the University of Freiburg has been doing. Researchers in the cluster have successfully produced an artificial muscle from elastin that functions autonomously.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-muscle-proteins-diverse-future-applications
Press release - 02/03/2022 Biorefinery project KoalAplan is extracting raw materials from wastewater The Ministry of the Environment, Climate Protection and the Energy Sector is funding the KoalAplan project, which extends the functional scope of a wastewater treatment plant. The project, based in the Stuttgart district of Büsnau, aims at recovering raw materials from wastewater and is therefore making a positive contribution to climate neutrality, as the products obtained replace fossil raw materials and energy-intensive processes.https://www.biooekonomie-bw.de/en/articles/pm/biorefinery-project-koalaplan-extracting-raw-materials-wastewater
Press release - 02/03/2022 HPV vaccination: Numerous studies provide impressive proof of effectiveness against cervical cancer More and more data from various European countries prove: Vaccination against human papillomavirus not only prevents precancerous lesions, but also reliably protects against cervical cancer. On the occasion of the International HPV Awareness Day on March 4, Nobel laureate Harald zur Hausen hopes that many more parents will recognize this unique opportunity to protect their children from preventable cancers by vaccinating against HPV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hpv-vaccination-numerous-studies-provide-impressive-proof-effectiveness-against-cervical-cancer
Press release - 02/03/2022 Pilot project RoKKa uses wastewater to produce fertiliser and raw materials The Ministry for the Environment, Climate Protection and the Energy Sector is funding the new research project RoKKa which is used to prove the viability of recovering raw materials from wastewater. This adds a crucial function to the scope of a conventional sewage treatment plant. Together with the operators of the sewage treatment plants in Erbach and Neu-Ulm, the project partners demonstrate the positive contribution towards climate protection…https://www.biooekonomie-bw.de/en/articles/pm/die-klaeranlage-der-zukunft-heisst-bioraffinerie
Press release - 01/03/2022 CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer® The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printer
Press release - 22/02/2022 Better understanding communication between neurons in the brain In the field of optogenetics, scientists investigate the activity of neurons in the brain using light. A team led by Prof. Dr. Ilka Diester and Dr. David Eriksson from the Optophysiology Laboratory at the University of Freiburg has developed a new method to simultaneously conduct laminar recordings, multifiber stimulations, 3D optogenetic stimulation, connectivity inference, and behavioral quantification on brains.https://www.gesundheitsindustrie-bw.de/en/article/press-release/better-understanding-communication-between-neurons-brain
Macrophages interacting with cytomegaloviruses - 22/02/2022 Cytomegaloviruses subvert macrophage identity Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.https://www.gesundheitsindustrie-bw.de/en/article/news/cytomegaloviruses-subvert-macrophage-identity
Natural fibers in use - 15/02/2022 Sustainable reinforcement of e-bike battery cases Ansmann AG from Assamstadt provides mobile energy solutions with a focus on sustainability. The BioBattery project, which was awarded the Baden-Württemberg Bioeconomy Innovation Prize, saw Ansmann AG working with the Fraunhofer LBF in Darmstadt to develop a natural fibre reinforced plastic composite for use in e-bike battery cases.https://www.biooekonomie-bw.de/en/articles/news/sustainable-reinforcement-e-bike-battery-cases
Press release - 10/02/2022 CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-participant-phase-1-study-multivalent-influenza-vaccine-candidate-based-second-generation-mrna-backbone-deve
Press release - 09/02/2022 Connecting fibres: The cellulose fibre industry impresses with innovation and vision The annual highlight of the industry is the International Conference on Cellulose Fibres in Cologne (www.cellulose-fibres.eu), where the latest innovations were showcased last week: new cellulose fibre technologies for various feedstocks and a wide range of hygiene and textile products as well as alternatives to plastics and carbon fibre for lightweight constructions.https://www.biooekonomie-bw.de/en/articles/pm/connecting-fibres-cellulose-fibre-industry-impresses-innovation-and-vision
Press release - 08/02/2022 New European Research Council grant for Max Plack Researcher The European Research Council is funding a large-scale proof-of-concept study on a new genome sequencing method called “Haplotagging”. Haplotagging is a new method for sequencing our genome with superior quality and faster speed, developed by group leader Frank Chan and his team at the Friedrich Miescher Laboratory at the Max Planck Campus, Tübingen, Germany.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-european-research-council-grant-max-plack-researcher
Press release - 03/02/2022 The 5G-OR Project is a Winner of the joint Franco-German Program for the Development of innovative Applications for 5G private Networks 5G-OR is one of the 4 winning projects jointly selected by the Federal Ministry of Economics and Climate Action in Germany and the Ministry of Economy, Finance and Relaunch in France for the call “Technical developments and application ecosystems for 5G private networks”. The joint Franco-German 5G-OR project takes up the challenge in the healthcare domain.https://www.gesundheitsindustrie-bw.de/en/article/press-release/5g-or-project-winner-joint-franco-german-program-development-innovative-applications-5g-private-networks
Press release - 02/02/2022 Animal Friends made of renewable resources fischertechnik has set a new milestone with the Animal Friends construction kit, as the building blocks and packaging are largely made of renewable resources and the models depict playful animals in new colours. The company is thereby taking another major step towards sustainability. The bio-based building set recently won the Toy Award, one of the most prestigious awards in the industry.https://www.biooekonomie-bw.de/en/articles/pm/animal-friends-aus-nachwachsenden-rohstoffen
Biosensor for whole blood and exhaled breath analysis - 02/02/2022 Antibiotic detection from whole blood or exhaled breath possible Incorrectly dosed antibiotics are not only dangerous for patients, but also often the cause of resistant strains of bacteria. Researchers at the University of Freiburg have developed a biosensor to determine the effective amount and thus enable personalised therapy. The biosensor works by rapidly determining small amounts of the substances directly from whole blood or exhaled breath.https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotic-detection-whole-blood-or-exhaled-breath-possible
Press release - 31/01/2022 Cancer research learns from space travel Researchers use epigenetic factors to investigate the role of stress in the development of tumor diseases. Experts believe that stress plays a major role in the development of tumors. One occupational group, for example, that experiences extreme stress over a short period of time is astronauts.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-research-learns-space-travel
Press release - 28/01/2022 New insights into predicting the efficacy of active ingredients in drug development Drugs consist of molecules developed in the drug laboratory that bind to their target, usually a protein, and thus exert their effect. The actual duration of binding of a drug molecule to its target protein varies depending on the drug. The lifetime of the drug-target complex can play a critical role in the efficacy of a drug, as a long residence time at the target can be crucial for the drug's action in some cases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-predicting-efficacy-active-ingredients-drug-development
Funding Venture Center of Excellence Funding programme, Funded by: EIT Health e.V. und European Investment Fund (EIF), sb_search.searchresult.label.programSubmissionDate: 31/12/2024 https://www.gesundheitsindustrie-bw.de/en/database/funding/venture-center-excellence
Funding Venture Center of Excellence Funding programme, Funded by: EIT Health e.V. und European Investment Fund (EIF), sb_search.searchresult.label.programSubmissionDate: 31/12/2024 https://www.gesundheitsindustrie-bw.de/en/database/funding/venture-center-excellence
Funding Venture Center of Excellence Funding programme, Funded by: EIT Health e.V. und European Investment Fund (EIF), sb_search.searchresult.label.programSubmissionDate: 31/12/2024 https://www.bio-pro.de/en/service/funding/venture-center-excellence
Press release - 28/01/2022 Artificial Muscles Made of Proteins Dr. Stefan Schiller and Dr. Matthias Huber from the University of Freiburg’s livMatS Cluster of Excellence have succeeded in developing a muscle solely on the basis of natural proteins. The autonomous contractions of the material, which the researchers presented in the journal Advanced Intelligent Systems, can be controlled with the help of pH and temperature changes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/artificial-muscles-made-proteins
Viral zoonoses - 24/01/2022 Development of inhibitors that help stop viral zoonoses Emerging viral infections such as COVID-19 or Zika disease pose an increasing threat to humans. At the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University, Prof. Dr. Christian Klein's research group is developing inhibitors against already known viruses in the hope that these can also be used against new virus variants.https://www.gesundheitsindustrie-bw.de/en/article/news/development-inhibitors-help-stop-viral-zoonoses
Press release - 18/01/2022 Metal strip refiner HUEHOCO is a new shareholder of carbonauten and acquires 5 percent of the shares The HUEHOCO GROUP Holding GmbH & Co. KG, a family-owned company from Wuppertal, North Rhine-Westphalia, has acquired a 5 percent stake in carbonauten GmbH. The start-up is in negotiations with further interested parties from Germany and Japan. With the international metal strip refiner HUEHOCO Group, which has sites on 4 continents, the "minus CO2 factory" has acquired its first industrial partner.https://www.biooekonomie-bw.de/en/articles/pm/metal-strip-refiner-huehoco-new-shareholder-carbonauten-and-acquires-5-percent-shares
microRNA as a prognostic biomarker - 13/01/2022 Heart attack diagnosis: fast and unambiguous thanks to artificial intelligence People that arrive in emergency rooms with chest pain require swift action in order to rule out a heart attack or to initiate vital life-saving therapy. However, despite many advances, current tests are not yet optimal: they either take hours or produce false-positive results. Researchers at Heidelberg University Hospital are now using AI in an approach that takes microRNAs from a blood sample to specifically diagnose ‘acute coronary syndrome’.https://www.gesundheitsindustrie-bw.de/en/article/news/heart-attack-diagnosis-fast-and-unambiguous-thanks-artificial-intelligence
Press release - 13/01/2022 Turning harmful CO2 into useful chemicals Making important raw materials for fine chemicals out of carbon dioxide really works. As part of the Max Planck collaborative project eBioCO2n, a team of researchers from Fraunhofer IGB have successfully performed a first ever fixation of CO2 via a multi-enzyme enzyme reaction driven by electricity yielding a prospective intermediate for the chemical industry. The process for electro-biocatalytic CO2 fixation was recently published and is…https://www.biooekonomie-bw.de/en/articles/pm/turning-harmful-co2-useful-chemicals
Protection against game damage - 13/01/2022 Sapling protectors made of domestic wood - simple but effective Young forest plants need protecting against damage and as a result it’s often hard to miss the colourful plastic tree guard sleeves when out walking in forests. These tree guard sleeves are neither pleasing to the eye nor sustainable. Bernd Schairer UG from Albstadt has developed sapling protectors made of wood that contain no plastics, metals or chemicals, do not require removal and disposal, and are produced in a socially responsible way.https://www.biooekonomie-bw.de/en/articles/news/sapling-protectors-made-domestic-wood-simple-effective
Press release - 12/01/2022 From insect carapace to sustainable building material Chitin is the main component of insect carapaces and ensures that they are both stable and flexible. The Chitinfluid research project, funded by the Carl Zeiss Foundation, focuses on the use of chitin in construction and aims to process chitin and its derivatives into sustainable materials. In a hybrid symposium under the auspices of Prof. Sabine Laschat from the University of Stuttgart, the project team discussed the current state of research…https://www.biooekonomie-bw.de/en/articles/pm/insect-carapace-sustainable-building-material
Press release - 11/01/2022 Obesity at a young age - a risk factor for early colorectal cancer The incidence of colorectal cancers in young adults is increasing. At the same time, the proportion of overweight and obese young people is also on the rise. Whether there is a connection between these two observations, however, was not known until now. Scientists at the DKFZ have now shown that the risk of early colorectal cancer is significantly increased in overweight young people compared to normal-weight peers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/obesity-young-age-risk-factor-early-colorectal-cancer
Press release - 10/01/2022 Algorithm identifies cancer drivers Genetic alterations that promote the development and spread of tumors are difficult to identify. This is especially true for mutations in the non-protein-coding regions of the genome, which include all important regulatory sequences. Scientists at the German Cancer Research Center have now published an algorithm that detects cancer drivers in both the protein-coding and non-coding regions of the genome.https://www.gesundheitsindustrie-bw.de/en/article/press-release/algorithm-identifies-cancer-drivers
Press release - 21/12/2021 Cochlear implant as a sensor The cochlear implant (CI) is the most successful neural prosthesis worldwide. Thanks to direct stimulation of the auditory nerve, it enables more than half a million people worldwide to hear, even though those affected were born deaf or deafened.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cochlear-implant-sensor
Press release - 20/12/2021 Immune microenvironment as a risk factor for colorectal cancer in Lynch syndrome Researchers at Heidelberg University Hospital (UKHD), the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have demonstrated for the first time that there is a link between the development of colorectal cancer in individuals with Lynch syndrome and the composition of immune cells in the colorectal mucosa.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-microenvironment-risk-factor-colorectal-cancer-lynch-syndrome
Press release - 18/12/2021 WHO publishes first classification of childhood tumors The International Agency for Research on Cancer (IARC), an agency of the World Health Organization (WHO), will soon publish the first edition of its classification of childhood cancers. The new WHO classification forms the basis of modern, precise cancer diagnostics for physicians and pediatric oncologists worldwide and is based on the latest international research findings.https://www.gesundheitsindustrie-bw.de/en/article/press-release/who-publishes-first-classification-childhood-tumors
Dossier - 16/12/2021 Advanced therapy medicinal products: gene and cell therapies Novel gene and cell therapies for treating incurable and hereditary diseases have raised high expectations. However, success has so far been limited to the long-established bone marrow transplants involving the administration of haematopoietic stem cells used to treat blood cancer. CAR T-cell therapies have recently emerged as a major new hope in cancer treatment.https://www.gesundheitsindustrie-bw.de/en/article/dossier/advanced-therapy-medicinal-products-gene-and-cell-therapies
Press release - 14/12/2021 Carbon fibres from wood - DITF nomination for the "Cellulose Fibre Innovation of the Year" award For the second time, the nova Institute for Ecology and Innovation is honouring outstanding scientific research that provides sustainable solutions for the cellulose fibre value chain as part of the "International Conference on Cellulose Fibres 2022". The DITF Denkendorf is one of the six nominees.https://www.biooekonomie-bw.de/en/articles/pm/carbon-fibres-wood-ditf-nomination-cellulose-fibre-innovation-year-award
Plant residues - 14/12/2021 Straw pulp: agricultural residues become sanitary paper products Straw cannot yet be spun into gold, but in Mannheim, Germany, it is being turned into something else of great value: Essity is the first and only company in Europe to produce toilet paper and kitchen rolls from wheat straw in a new pulp mill. From next year, these sustainable sanitary paper products will be found on supermarket shelves.https://www.biooekonomie-bw.de/en/articles/news/straw-pulp-agricultural-residues-become-sanitary-paper-products
Press release - 14/12/2021 EU regulation approved: G-BA collaborates on European health technology assessment Today, the EU Parliament adopted the EU Regulation on Health Technology Assessment (HTA), which includes not only new medicines (including gene and cell therapies), but also medical devices.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-regulation-approved-g-ba-collaborates-european-health-technology-assessment
Press release - 09/12/2021 New research project in mathematical oncology A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-research-project-mathematical-oncology
Renewable raw materials and the circular economy in the textile industry - 08/12/2021 Outdoor equipment made from cellulose, castor oil and coffee grounds - functional and durable VAUDE develops outdoor gear made from natural or recycled materials that are harmless to people and the environment while protecting against the wind and rain. The company relies on renewable raw materials, biobased plastics and the circular economy.https://www.biooekonomie-bw.de/en/articles/news/outdoor-equipment-made-cellulose-castor-oil-and-coffee-grounds-functional-and-durable
Press release - 07/12/2021 Moderate immune response is more effective against leukemia The development of immunotherapies against blood cancer could be more successful if T cells are activated moderately rather than excessively. Scientists from the German Cancer Research Center have now been able to show this in mice: If the researchers blocked a cytokine that slows down the immune system, the T cells became exhausted and failed in the fight against leukemia.https://www.gesundheitsindustrie-bw.de/en/article/press-release/moderate-immune-response-more-effective-against-leukemia
Press release - 07/12/2021 New approach developed to predict response of immunotherapies in lung cancer At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-developed-predict-response-immunotherapies-lung-cancer